TIVA for tonsillectomy Peter Squire, RCH

Airway protection Apnea monitoring +/-' post-op ventilation (HDU or PICU) Safe environment Extended analgesia

477 cases of under 12yo T&A's (Feb 13-Feb14) Incr. with 'blitz lists' Approx 10-12 per week, *far less than other centres!*



Advantages of Sevo

- "You just breathe it"
- Treats needle-phobic parents
- Doesn't need EMLA or Angel
- You don't have to prepare it
- You can assess the degree of airway obstruction
- 'Relatively' quick offset
- Gives you 101 chances to get the cannula in!







Disadvantages of Sevo

- "It stinks"
- It pollutes
- Requires a vaporiser
- Makes you chuck (PONV)
- Makes you mad (Emergence Agitation)
- Gives you laryngospasm
- Puts the surgeon to sleep
- Malignant Hyperthermia
- Rhabdomyolysis





Malignant Hyperthermia vs Rhabdomyolysis

British Journal of Anaesthesia 104 (4): 487–9 (2010) doi:10.1093/bja/aeq035 Advance Access publication February 26, 2010

PAEDIATRICS

Case Report

Perioperative cardiac arrest in a patient with previously undiagnosed Becker's muscular dystrophy after isoflurane anaesthesia for elective surgery[†]

T. C. Poole^{1*}, T. Y. J. Lim², J. Buck² and A. S. Kong¹

Central core disease (MH) Known spontaneous Rhabdomyolysis Muscular dystrophy Duchenne's





Benefits: Post-operative nausea and vomiting



A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents

J. R. Sneyd, A. Carr, W. D. Byrom* and A. J. T. Bilski* Department of Anaesthesia, Derriford Hospital, Derriford Road, Plymouth PL68DH, UK * Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire, UK

European Journal of Anaesthesiology 1998, 15, 433-5 70 trials (57 adult, 13 children) 4074 vomiting as end-point; 3516 nausea; 742 n and v

"3.5 and 5.7-fold reductions in vomiting in adults and children when propofol used "







BJA 2002; 88(5):659-68 Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design C.C Apfel et al

5 way factorial design (gender, type of surgery, anaesthetic maintenance, opiod use, antiemetic use)

1180 patients (593 children) elective ENT or strabismus surgery

Strongest risk factor for vomiting was use of volatile anaesthetics compared with propofol (Odds ratio for Iso and Sevo were 3.4 and 2.8)









BJA 2002; Apfel et al (ctd)

Early post-op period (0-2 hrs) showed volatiles as also being the clear risk factor (40% PONV cw 10% PONV with propofol) (Adjusted Odds ratios: Iso 19.8, Sevo 14.5)

Depends somewhat on degree of exposure

"Irrespective of volatile type this factor alone was *several orders of magnitude* stronger than all other factors (including antiemetics) in early post-op period"



Anesth Analg 2003; 97:62

"PONV is debilitating, costly and prevalent"

2X incr vomiting in children

Adenotonsillectomy, squint repair, herniae, orchiopexy and penile surgery

Use of Propofol and avoiding volatiles was most efficacious measure (1A evidence)

Should we be extending the benefit to paediatric day-case?

SPECIAL ARTICLE

ANALGESIA

ANESTHESIA &

Consensus Guidelines for Managing Postoperative Nausea and Vomiting

Tong J. Gan, MD*, Tricia Meyer, MS, FASHP†, Christian C. Apfel, MD‡, Frances Chung, FRCPC§, Peter J. Davis, MD|, Steve Eubanks, MD¶, Anthony Kovac, MD#, Beverly K. Philip, MD**, Daniel I. Sessler, MD++, James Temo, CRNA, MSN, MBA⁺, Martin R. Tramèr, MD, DPhil§§, and Mehernoor Watcha, MD||

Departments of *Anesthesiology and ¶Surgery, Duke University Medical Center, Durham, North Carolina; †Departments of Pharmacy and Anesthesiology, Scott and White Memorial Hospital, Texas A&M University System HSC College of Medicine, Temple, Texas; ‡Outcomes Research™ Group and Department of Anesthesiology, University of Wuerzburg, Wuerzburg, Germany; §Department of Anesthesiology and Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; #Department of Anesthesiology, University of Kansas Medical Center, Kansas City, Kansas; **Department of Anesthesiology and Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; #Department of Anesthesiology, University of Kansas Medical Center, Kansas City, Kansas; **Department of Anesthesiology and Pharmacology, University of Louisville, Louisville, Kentucky; ‡‡Duke University Nurse Anesthetist Program, Durham, North Carolina; §\$Division of Anesthesia, Geneva University Hospital, Geneva, Switzerland; and ∥Department of Anesthesia, Carolina; §Division of Anesthesia, Philadelphia, Pennsylvania

Postoperative nausea and vomiting (PONV) continues to be a common complication of surgery. It is a limiting factor in the early discharge of ambulatory surgery patients and is a leading cause of unanticipated hospital admission (1,2). PONV can lead to increased recovery room time, expanded nursing care, and potential hospital admission—all factors that may increase total health care costs. Equally important are the high levels of patient discomfort and dissatisfaction associated with PONV. Patients report that avoidance of PONV is of greater concern than avoidance of postoperative pain (3) and are willing to spend up to US\$100 out of pocket for an effective antiemetic (4), yet more than a quarter of patients continue to experience PONV within 24 h of surgery (5,6). Among high-risk patients, the incidence of PONV can be as frequent as 70% to 80% (7). Published evidence suggests that universal PONV prophylaxis is not cost-effective. Although some advocate prophylactic antiemetic therapy for high-risk patients and rescue antiemetic treatment for episodes of PONV, the optimal approach to PONV management remains unclear to many clinicians. Guidelines for prevention and treatment of PONV based on data from systematic reviews of randomized trials have been published (8,9). However, these guidelines did not consider ev-

-



Supported by an unrestricted educational grant from Aventis, Inc. The company had no input into the content of this article.

The following authors have conflicts of interest or potential conflicts of interest. T. J. Gan-speaker's bureau: Pharmacia, Abbott, GlaxoSmithKline, Merck; research support: Pharmacia, Abbott, GlaxoSmithKline, Aspect, and Roche; consultant: Pharmacia, Abbott, Roche, and GlaxoSmithKline. T. Meyer-speaker: Aventis, Abbott, Baxter, and Novartis Consumer Health. C. C. Apfel-honoraria and

Benefits: Post Anaesthesia Emergence Delirium (PAED)







Emergence Agitation After Sevoflurane Versus Propofol in Pediatric Patients

Shoichi Uezono, MD, Takahisa Goto, MD, Katsuo Terui, MD, Fumito Ichinose, MD, Yoshiki Ishguro, MD, Yoshinori Nakata, MD, MBA, and Shigeho Morita, MD Department of Anesthesiology, Teikyo University and Ichihara Hospital, Chiba, Japan



16 retinoblastoma kids1-5 yoAll had Sevo inductionRandomised to Sevo or PropofolHad alternate agent for next exam

Table 2. Recovery Characteristics

Propofol	Sevoflurane
16 ± 7	13 ± 4
32 ± 16	$19 \pm 8^{+}_{$
43 ± 10	$29 \pm 6^{*}$
139 ± 71	167 ± 79
0 (0)	6 (38)†
0	2
0	3
0	1
0	2 (13)
5 (1)	4 (1.3)†
	$\begin{array}{c} Propofol \\ 16 \pm 7 \\ 32 \pm 16 \\ 43 \pm 10 \\ 139 \pm 71 \\ 0 \ (0) \\ \end{array} \\ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 5 \ (1) \end{array}$

....good study but small numbers!



Study design	Population	Premedication	emedication Analgesia EA inci	
Sevoflurane only				
Sevoflurane vs propofol induction/halothane maintenance ¹⁰	322 children Age 3-12 y Day surgery or ENT surgery	None	Alfentanil, fentanyl, or regional blocks	Sevoflurane 25.7% Propofol/halothane 9.4%
Sevoflurane vs sevoflurane induction, isoflurane maintenance ⁶	128 children Age 1-6 y Subumbilical surgery	None	Penile, caudal, or ilioinguinal/ iliohypogastric block	Sevoflurane 51.8% Sevoflurane/isoflurane 32.1%
Sevoflurane only ²¹	68 children Age 1-6 y Circumcision	Midazolam 0.5 mg/kg, or clonidine 2 or 4 µg/kg	Penile block and rectal paracetamol 30 mg/kg	Midazolam 60% Clonidine 2 µg/kg 40%, 4 µg/kg 25%
Total intravenous anesthesia (TIVA)				
Sevoflurane vs propofol TIVA ¹³	53 children 2-36 mo Ambulatory surgery	None	Fentanyl 2 µg/kg or caudal block	Sevoflurane 23.1% Propofol 3.7%
Sevoflurane vs propofol TIVA ¹⁵	186 children Age 2-11 y ENT surgery	None	Fentanyl 2 µg/kg	Sevoflurane 20%-42% Propofol 5%-11%
Sevoflurane vs propofol TIVA ¹⁶	88 children Age 2-6 y MRI	None	None	Mean PAED scale score significantly lower for propofol group
Sevoflurane vs propofol TIVA ¹⁷	50 children Age 3-10 y Tonsillectomy	None	Alfentanil 20 µg/kg, acetaminophen 20 mg/kg or ibuprofen 10 mg/kg, and local infiltration of site	Sevoflurane 46% Propofol 9%
Sevoflurane vs propofol TIVA ⁹	16 children Age 1-5 y Eye surgery	Midazolam 0.5 mg/kg PO	Acetaminophen 30 mg/kg prn	Sevoflurane 38% Propofol 0%
Propofol as adjunct to sevoflurane				
Propofol 1 mg/kg vs saline ⁵	80 children Age 2-6 y Strabismus surgery	Midazolam 0.5 mg/kg PO	Paracetamol 15 mg/kg IV	Propofol 19.5% Saline 47.2%
Propofol 1mg/kg vs saline ¹⁴	84 children Age 2-7 y MRI	None	Nitrous oxide	Propofol 4.8% Saline 26.8%

Table 3. Emergence Agitation (EA) Studies Divided by Anesthetic Technique With EA Incidence ENT indicates ear, nose, and throat: PAED, Pediatric Anesthesia Emergence Delirium; MRI, magnetic resonance imaging; prn. as



AANA Journal Dec 2010 Vol 78, p471

MELBOURNE

Murdoch Childrens Research Institute

Benefits: Laryngospasm/ Bronchospasm

THE LANCET

Risk assessment for respiratory complications in paediatric anaesthesia: a prospective cohort study

Britta S von Ungern-Sternberg, Krisztina Boda, Neil A Chambers, Claudia Rebmann, Chris Johnson, Peter D Sly, Walid Habre

Lancet 2010; 376; p773 Prospective multivariate analysis 9297 questionnaires



Cost of anaesthetic



Fentanyl (100 mcg) 57¢ Dexamethasone (8mg) 88¢ Tramadol (100mg) 77¢ N.Saline (500ml) \$1.27 IV Paracetamol (500 mg) \$ 2.34 Remifentanil (1mg) \$3.30 Granisetron (1 mg) \$7.25 Clonidine (150 mcg) \$9.20 Parecoxib (40 mg) \$16.60 Isoflurane bottle (250 ml) \$88 Sevoflurane bottle (250 ml) \$142.50

Propofol (200mg) 77¢



Volatile consumption

										Children's
Agent	MW	MAC % (Datex default for 3yr old pt)	Volume volatile / litre gas flow @ 1 MAC	Volume of 1ml of volatile at 20oC	portion of a ml of volatile per Itr FGF @ 1 MAC	Cost of bottle	Volume bottle	Cost per ml	Cost of 1 MAC in 1 I FGF per minute	Cost of 1 MAC for 1 hour
Sevoflurane	200	2.65	26	182	0.143	147	250	\$0.59	\$0.08	\$5.04
Isoflurane	184.5	1.5	15	195	0.077	80	250	\$0.32	\$0.02	\$1.48
Desflurane	168	7.8	78	208	0.375	235	240	\$0.98	\$0.37	\$22.03

Volume of sevo at 8% per I FGF	Volume of 1ml of volatile at 20oC	portion of a ml of volatile per Itr FGF	Cost of bottle	Volume bottle	Cost per ml	Cost of 8% Sevo for litre FGF per minute	Cost c Sevo minut 6l F	of 8% per e for GF
80	182	0.440	147	250	\$0.59	\$0.26	\$1.	55
	5.0							
				The Children's Excellence in clinical care, research and education	The Royal Children Hospital Metocurre	Murdoch Childrens Research Institute	THE UNIVERSITY OF MELBOURNE	













Taking TIVA outside RCH

Dr.Balvíndar Kaur Staff Anaesthetíst





Health for Humanity



Surgical non profit mission working in the Obras Hospital, Antigua Guatemala

Performed over 180 surgeries in 10 days of operating

Over 50 palate and lip repairs with an average of 4-8 cases a day in 2





The Set Up and Recipe

SET UP

- Mostly IV inductions
- T-piece connected to patient
- 2mg/kg propofol, 10mcg/ kg remifentanil
- Propofol/remi mixture of 10mg/ml; 2.5-5mcg/ml
- 250-300mcg/kg/min
- Spont vent on Ayre's Tpiece circuit

ADVANTAGES

- Smooth wake up
- No need to rely on anaesthesia machine-old, adult ventilator
- Minimal airway irritation and no incidence of laryngospasm
- Preferred wake up by recovery staff who had limited paediatric

Murdoch Childrens Research

MELBOURNI

EXPOSUREIdren's

